How we work

We campaign to ensure that the medicinal cannabis industry, those who conform with acknowledged scientific standards of quality, safety and efficacy, are represented with governments and regulators throughout the European Union at the highest level.

By engaging with European governments and regulators, we can create credible, lasting partnerships and coherent policy frameworks, encompassing important areas including: Research & Development; Manufacturing; Regulatory; Patient Access & Reimbursement.

We use specialist working groups and expert networks to cover most industry hot topics. These groups are made up of representatives of member companies with special interest and expertise in these areas. This means that we can react quickly to any new issues as they arise. It is these groups which help us to draw up responses to government consultations.

How we work

We campaign to ensure that the medicinal cannabis industry, those who conform with acknowledged scientific standards of quality, safety and efficacy, are represented with governments and regulators throughout the European Union at the highest level.

By engaging with European governments and regulators, we can create credible, lasting partnerships and coherent policy frameworks, encompassing important areas including: Research & Development; Manufacturing; Regulatory; Patient Access & Reimbursement.

We use specialist working groups and expert networks to cover most industry hot topics. These groups are made up of representatives of member companies with special interest and expertise in these areas. This means that we can react quickly to any new issues as they arise. It is these groups which help us to draw up responses to government consultations.

Key pillars

By working together, the EUMCA promotes the development of national government healthcare policies that advocate the ethical prescription of pharmaceutical-grade medicinal cannabis, and advance patient access to treatments.  It does this through:

Collaborating with EU stakeholders to inform the policy debate in order to create a harmonised prescribing framework

Promoting scientific medical research and policy to support the standardised, ethical, and sustainable use of medicinal cannabis

Working with national reimbursement institutions to improve patient access to medical cannabis-based treatments

Providing evidence-based knowledge and learning on medicinal cannabis to healthcare professionals and patients

Developing and reviewing policies and procedures which raise awareness of legal compliance, ethics and changes in regulation

Providing members with counsel and guidance on regulatory affairs

Delivering networking opportunities for members focused on building their business through M&A, licensing, partnering and novel in-market strategies

The objectives of the Association (the “Objectives”) shall be:

1. Representing member companies and associations operating in Europe in research, development, growing, manufacturing and distribution in the medicinal cannabinoid treatments in respect to international governmental organizations in particular towards the European institutions, EU agencies and national agencies
2. Representing member companies and associations in Europe interested in supporting companies research, development, growing, manufacturing and distribution in medicinal cannabinoid treatment
3. Informing national and European institutions and EU agencies of the views of the medicinal cannabinoid industry (primary care as well hospital care) on all matters that are of interest to it and concern public health, in particular international legislation and regulations in Europe
4. Strengthening the awareness of the value of the European medicinal cannabinoid industry and its products for patient health and the economy, based on ethical practices
5. Coordinating common interests and activities in dealings with national and European institutions and authorities and associations in the EU/EEA member states
6. Enhancing medicinal research and development through promotion and cooperation across national borders
7. Establishing a qualified network for the medicinal cannabinoid industry
8. Cooperating with national and international organisations having similar objectives
9. Establishing and promoting a European Compliance Declaration for the medicinal Cannabinoid Industry

The Association performs the following activities with a view to achieving the objectives described under article 3.2. above:

1. Organising regular high-level national and international meetings for the responsible business leaders representing the member companies, associations and healthcare stakeholders
2. Supporting professional, medical and scientific relationships between its members by organizing periodical meetings
3. Supporting professional, medical and scientific relationship between its members and healthcare stakeholders by organizing periodical meetings
4. Supporting its members with regular information on the development of the legal framework for the medicinal cannabinoid industry in Europe
5. Preparing information and position papers and disseminating national and European governmental institutions’ policies
6. Monitoring political, legal, scientific and economic developments in the EU relevant to the medical cannabinoid industry
7. Collecting, expressing and exchanging common positions in order to provide to European and member state institutions with unified and representative industry positions
8. Maintaining close relations with governmental and non-governmental bodies in order to enhance understanding of problems affecting the European medical cannabinoid industry
9. Facilitating the promotion and distribution of information in relation to professional groups and the general public, i.e. health care providers and their associations, health insurance organisations, consumers and other interested stakeholders for medicinal cannabinoid treatments and companies
10. Organising information meetings on projects in the European Commission’s programs for research and development relevant for the medical cannabinoid industry
11. Supporting joint edition and distribution of publications which promote the objectives of the Association